Logo

ITRM

Iterum Therapeutics plc

ITRM

Iterum Therapeutics plc • NASDAQ
$0.46 ▼ -1.94% (-0.01)
Market Cap $22.10 M
52w High $3.02
52w Low $0.36
Dividend Yield 0%
P/E -0.64
Volume 433.02K
Outstanding Shares 48.05M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $390K ▲ $7.752M ▲ $-8.979M ▼ -2.302K% ▼ $-0.2 ▼ $-8.051M ▼
Q2-2025 $0 $4.833M ▲ $-6.509M ▼ 0% $-0.16 ▼ $-5.65M ▼
Q1-2025 $0 $3.368M ▼ $-4.891M ▲ 0% $-0.14 ▲ $-3.948M ▲
Q4-2024 $0 $3.67M ▼ $-6.582M ▼ 0% $-0.25 ▲ $-5.422M ▼
Q3-2024 $0 $4.887M $-6.094M 0% $-0.3 $-5.36M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $11.002M ▼ $32.503M ▼ $39.884M ▲ $-7.381M ▼
Q2-2025 $13.026M ▲ $34.014M ▲ $37.901M ▲ $-3.887M ▼
Q1-2025 $12.652M ▼ $32.975M ▼ $35.529M ▼ $-2.554M ▲
Q4-2024 $24.125M ▲ $44.595M ▲ $48.676M ▲ $-4.081M ▲
Q3-2024 $14.502M $15.924M $27.431M $-11.507M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-8.979M ▼ $-7.848M ▼ $-12.566K ▼ $5.658M ▲ $-2.024M ▼ $-7.86M ▼
Q2-2025 $-6.509M ▼ $-4.751M ▼ $0 ▲ $5.12M ▲ $374K ▲ $-4.751M ▼
Q1-2025 $-4.891M ▲ $-3.06M ▲ $-2K ▼ $-8.388M ▼ $-11.473M ▼ $-3.062M ▲
Q4-2024 $-6.582M ▼ $-4.256M ▼ $1.1M ▼ $13.877M ▲ $10.719M ▲ $-4.256M ▼
Q3-2024 $-6.094M $-2.672M $5.7M $5.43M $8.43M $-2.672M

Five-Year Company Overview

Income Statement

Income Statement Iterum has effectively been a pure R&D company so far, with no product revenue reported over the past several years and recurring operating losses. Costs appear relatively lean for a biotech, but they still clearly exceed income, so the business has not yet come close to break-even. Net losses have been consistent, reflecting ongoing spending on development and regulatory work rather than any commercial scale. The very large swings in earnings per share are mostly a function of capital structure changes (like the reverse split) rather than sudden changes in underlying business performance.

Balance Sheet

Balance Sheet The balance sheet is small and tight. The company holds a modest cash balance and a limited pool of total assets, while carrying a notable amount of debt relative to its size. Shareholders’ equity has hovered around breakeven, at times dipping negative, which signals a thin capital cushion and a reliance on outside financing to keep operations going. Overall, financial flexibility looks constrained, and the company’s ability to weather setbacks is more limited than that of larger, better-capitalized peers.

Cash Flow

Cash Flow Cash flow is consistently negative, reflecting ongoing operating expenses with no offsetting revenue yet. There is essentially no spending on heavy equipment or facilities, so almost all cash outflow is tied to people, trials, and overhead, not long-lived assets. This means the company’s cash runway depends heavily on its starting cash balance and its ability to raise new funds. As Iterum moves from development into commercialization of ORLYNVAH™, launch and marketing costs could keep cash burn elevated before any meaningful inflows develop.

Competitive Edge

Competitive Edge Scientifically, Iterum occupies a differentiated niche: it has the first and only approved oral penem antibiotic, aimed at resistant urinary tract infections where oral options are limited. This provides a clear clinical story, regulatory exclusivity, and a head start in a focused market segment. Strong patent coverage and the U.S. QIDP exclusivity boost its defenses against direct competitors. However, antibiotics are a notoriously difficult commercial area, with pricing pressure, stewardship restrictions, and conservative prescribing habits. The company is also highly dependent on the success of a single product in a narrow initial indication, which heightens both the upside and the risk.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of Iterum’s value: it has taken a challenging antibiotic class and successfully created an oral formulation with a strong scientific rationale and supportive trial data. The strategy now centers on building a “sulopenem franchise,” with potential expansion into an intravenous version and additional infection types. This focused R&D approach allows deep specialization, but it also concentrates risk in one technology and one mechanism. Future progress will depend on the company’s ability to fund additional trials, execute lifecycle studies, and demonstrate real-world value to physicians and payers, all while managing a limited budget.

Summary

Iterum is a small, early-commercial-stage biotech built around a single, differentiated antibiotic platform. On the positive side, it has achieved something rare in antibiotics: a novel oral product with clear regulatory advantages and protection, aimed at an area of genuine unmet medical need. On the risk side, the company remains pre-revenue in its reported history, with recurring losses, a very lean balance sheet, and persistent cash burn. Financially, this leaves little room for missteps and suggests ongoing dependence on new capital or partnerships. The overall picture is a high-risk, high-uncertainty profile where the company’s future will largely hinge on how effectively it can launch ORLYNVAH™, secure additional indications, and maintain access to funding along the way.

NEWS

November 24, 2025 · 8:00 AM UTC

Iterum Therapeutics Provides Business Update

Read more

November 14, 2025 · 7:00 AM UTC

Iterum Therapeutics Reports Third Quarter 2025 Financial Results

Read more

November 7, 2025 · 8:00 AM UTC

Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025

Read more

October 14, 2025 · 8:30 AM UTC

Iterum Therapeutics to Present Data at IDWeek 2025

Read more

September 19, 2025 · 8:00 AM UTC

Iterum Therapeutics Provides Business Update

Read more